NTLA250117C7500
- 7.10
- 0.000.00%
Intellia Therapeutics Newsroom
Beam Upgraded by Bernstein Ahead of AATD Data
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $47
RBC Cuts Price Target on Intellia Therapeutics to $47 From $54, Keeps Outperform, Speculative Risk
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $50
Intellia Therapeutics Price Target Lowered to $50 From $58 at BofA
Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?
Peering Into Intellia Therapeutics's Recent Short Interest
Cathie Wood's ARK Investment Buys 96.2K Shares of Intellia Therapeutics Today
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?
Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025
Express News | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
Promising Outlook for Intellia Therapeutics' Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost